Results 121 to 130 of about 287,802 (318)
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera
Haematologica, 2009 To further characterize JAK2 exon 12 mutations, we performed molecular screening in 409 patients with polycythemia vera or unclear erythrocytosis with unmutated JAK2V617. The frequency of JAK2exon12 mutations was 10/63 (15.9%) in PV but only 5/346 (1.4%)
Susanne Schnittger +14 more
doaj +1 more source
Idiopathic noncirrhotic portal hypertension: current perspectives [PDF]
, 2016 The term idiopathic noncirrhotic portal hypertension (INCPH) has been recently proposed to replace terms, such as hepatoportal sclerosis, idiopathic portal hypertension, incomplete septal cirrhosis, and nodular regenerative hyperplasia, used to describe ...
D'AMATI, Giulia +5 more
core +1 more source
Treatment of polycythemia vera [PDF]
Vnitřní lékařství, 2018 Polycythemia vera is a chronic myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation resulting in erythrocytosis, leukocytosis and thrombocytosis. Survival is reduced compared with general population.
openaire +3 more sources
Mechanisms of thrombogenesis in polycythemia vera
Blood Reviews, 2015 Thrombotic and cardiovascular events are among the leading causes of death for patients with polycythemia vera (PV), and thrombosis history is a key criterion for patient risk stratification and treatment strategy. Little is known, however, about mechanisms of thrombogenesis in patients with PV.
Srdan Verstovsek +2 more
openaire +3 more sources
Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
Blood Advances, 2016 Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; we describe the occurrence and prognostic relevance of DNA sequence variants ...
A. Tefferi +15 more
semanticscholar +1 more source
What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson +5 more
wiley +1 more source
Superior Vena Cava Syndrome in a Patient with Polycytemia Vera: Diagnosis and Treatment
Cardiology Research and Practice, 2010 Polycythemia vera is a myeloproliferative disorder characterized by thrombotic complications both in the arterial and venous systems. We report the case of a 55-year-old patient affected by polycythemia vera, presenting with acute superior vena cava ...
Salvatore Lentini +3 more
doaj +1 more source
Koljusisesed verevalumid tõelise polütsüteemiaga haigel kerge trauma järel [PDF]
, 2017 Tõelise polütsüteemia diagnoosiga 54aastasel naishaigel kujunesid pärast kerget traumat – omalt jalalt kukkumist – ajusisene ja subduraalne verevalum vasemas ajupoolkeras.
Hein, Marju +3 more
core +2 more sources
Predicting optimal hematocrit in silico [PDF]
, 2018 Optimal hematocrit $H_o$ maximizes oxygen transport. In healthy humans, the average hematocrit $H$ is in the range of 40-45$\%$, but it can significantly change in blood pathologies such as severe anemia (low $H$) and polycythemia (high $H$). Whether the
Audemar, Vassanti +11 more
core +6 more sources
Chorea disclosing a polycythemia vera
Neuropsychiatric Disease and Treatment, 2014 Chorea is a rare complication of polycythemia. We report the case of a 70 year-old woman whose polycythemia vera (PV), with Janus Kinase-2 (JAK2) mutation, presented as chorea. Chorea resolved quickly after hydroxyurea therapy.
Yingying Zhang +6 more
openaire +5 more sources